Press Releases and News

VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Thailand, registered as a Class 1 medical device with the Thai Food and Drug Administration (Thai FDA). The approval marks an important milestone in VibroSense expansion in Southeast Asia.

On 31 August 2026, VibroSense Dynamics AB (publ) received a visit from the Institute of European Studies (IES) at the Chinese Academy of Social Sciences (CASS) – China’s national policy research institute for European affairs. The delegation consisted of Professor Jia Ruixia and Professor He Zhigao, Head of the Department of European Politics. The visit reflects the international interest in VibroSense’s technology and the company’s commitment to the Chinese life science market.

VibroSense Dynamics AB (publ) has initiated legal proceedings to address a breach of the exclusive agreement signed with VibroSense's Chinese distributor Genertec Universal Medical Group Co., Ltd (UMCare), a subsidiary of General Technology (Group) Holding Co., Ltd. UMCare is listed on the Hong Kong Stock Exchange.
    

VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Turkey through MDR registration completed by the company’s Turkish distributor Alpmed Tibbi Cihazlar. The approval gives Alpmed the green light to begin commercial sales of the instrument in the Turkish market, with full support from VibroSense Dynamics.
 

VibroSense Dynamics AB (publ) announces today that a distribution agreement has been signed with Fu Kang Healthcare Supply Pte Ltd, a Singapore-based company specialising in distribution of orthopaedic and rehabilitation products. The agreement grants Fu Kang Healthcare the right to market and sell VibroSense Meter® II in Singapore.                 

New research published in the Journal of the Peripheral Nervous System (Sloan et al., 2026) shows that the understanding of peripheral nerve damage caused by diabetes (DPN) is shifting. DPN has long been regarded as irreversible, but a growing number of studies suggest that nerve damage can be reversed, especially if the condition is detected early.

VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Singapore, listed as a Class A medical device with the Health Sciences Authority (HSA). The approval marks an important milestone in VibroSense’s expansion into the Asia-Pacific region.                   

VibroSense Dynamics AB (publ) announces today that a distribution agreement has been signed with Sparqmed, a newly started medical device distributor based in Warsaw, Poland. The agreement grants Sparqmed the right to market and sell VibroSense products in the Polish market.

VibroSense Dynamics AB (publ) announces today that the company has signed a distribution agreement with Alpmed Tibbi Cihazlar, a medical device distributor active in the Turkish market. The agreement grants Alpmed the right to market and sell VibroSense products in Turkey, marking the company’s entry into the Turkish market.
    

VibroSense Dynamics AB (“VibroSense”) has been granted a patent in Japan on a Biomarker to predict the risk of developing permanent nerve damage caused by chemotherapy (CIPN) at treatment of cancer.

The granted patent claims in Japan correspond to those previously granted by the European Patent Office (EPO). The patent strengthens the company’s intellectual property protection and complements existing safeguards including encrypted algorithms in the software of the company’s hand and foot instruments.

VibroSense Dynamics AB (publ) has signed a tripartite research agreement with the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust . The collaboration agreement concerns a research study that aims to evaluate a new treatment to relieve pain in patients with diabetes, so-called painful diabetic neuropathy (pDPN).

During the fall of 2025, the company has accelerated its international launch of the medical device  product VibroSense Meter®II. Significant progress has been made on several fronts, from contacts with potential distributors to research within the prioritized segments, diabetes, oncology and occupational healthcare.

The first delivery of VibroSense Meter II instruments to China is delayed to the spring of 2026 due to organizational changes and uncertainties at VibroSense’s distributor UMCare in China. The binding distribution agreement with UMCare remains in force; however, it will not generate previously anticipated revenues during the autumn of 2025.

With “the Company” or “VibroSense” is meant VibroSense Dynamics AB (publ) with registration number 556669–2223. Amounts in parentheses in this report refer to the corresponding period of the previous year. The Company previously applied a broken financial year until the last Annual General Meeting, at which it was decided to change the Company’s financial year from a broken fiscal year (1 July – 30 June) to a calendar year (1 January – 31 December). Therefore, the current financial year will cover a period of 18 months (6 quarters) and extend until 31 December 2025.

VibroSense Dynamics AB (publ) enters the autumn with a strengthened organisation, new patent advancements, and preparations for the launch of VibroSense Meter® II in China.

On September 1st, company co-founder Toni Speidel assumed the role of CEO. Simultaneously, the marketing and sales team was strengthened with the addition of two new Marketing & Sales Specialists. To further support the company’s expansion in China, a local Key Account Manager has also been appointed for the Chinese market.

VibroSense Dynamics AB (“VibroSense”) has received an Intention to Grant from the European Patent Office (EPO) regarding a patent on a Biomarker to predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy.

The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer.

VibroSense Dynamics AB (publ) announces today that the company has received the official certificate from the Chinese pharmaceutical authority NMPA (National Medical Products Administration). The company had previously informed the market that the NMPA approval had been granted, and with the formal certificate in hand, the three-year commercial agreement with the exclusive Chinese partner UMCare now comes into effect.

The agreement, which has a total value of approximately EUR 3.74 million, covers the launch, marketing and sales of VibroSense products in the Chinese market.

VibroSense Dynamics AB (publ) has signed a research agreement with the renowned Diabetic Foot Unit at the Complutense University of Madrid. The purpose of the collaboration is to validate the VibroSense Meter® II in clinical practice and to objectively compare the technology with current standard methods used to diagnose diabetic neuropathy.

VibroSense Dynamics AB (publ) announces today that its medical device, VibroSense Meter® II, has been approved by the National Medical Products Administration (NMPA) in China.

VibroSense Dynamics AB has received a European patent on a principle that measures skin temperature automatically and wirelessly, before and during an examination, which ensures measurement quality. The patent is a so-called European patent (Unitary Patent) which has been extended by two additional countries.